Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma

Journal of the American Academy of Dermatology

Volumn 43, Issue 6, 2000, Pages 991-1000

  Henrique, Rui ^a   Azevedo, Rosa ^a   Bento, Maria José ^a   Domingues, José Carlos ^a   Silva, Cristina ^a   Jerónimo, Carmen ^a  

^a Portuguese Cancer Institute   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; KI 67 ANTIGEN; PARAFFIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033664108     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.109282     Document Type: Article

References (40)

1. Malignant melanoma: Perspectives on incidence and its effects on awareness, diagnosis and treatment
2. Cancer statistics, 1997
3. A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's methods
4. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.99 mm)
5. The nature of melanoma: A critical review
6. Tumor thickness and prognosis in clinical stage I malignant melanoma
7. Thickness, cross-sectional area, and depth of invasion in the prognosis of cutaneous melanoma
8. The prognosis of primary and metastasising melanoma: An evaluation of the TNM classification in 2,495 patients
9. Predicting survival and recurrence in localized melanoma: A multivariate approach
10. Primary cutaneous melanoma: Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification
11. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer
12. The prognostic value of Ki67 immunostaining in non-Hodgkins lymphoma
13. Cell proliferation kinetics in human solid tumors: Relation to probability of metastatic dissemination and long-term survival
14. Growth fractions in malignant non-Hodgkin's lymphomas as determined in situ with the monoclonal antibody Ki-67
15. Immunohistochemical determination of growth fractions in human permanent cell lines and lymphoid tumors: A critical comparison of the monoclonal antibodies OKT9 and Ki-67
16. Cell cycle-dependent reactivity with the monoclonal antibody Ki 67 during myeloid cell proliferation
17. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7)
18. Computer simulation analysis of morphological patterns in human melanocytic skin tumors
19. Cell kinetics as a prognostic tool in patients with metastatic malignant melanoma of the skin
20. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions
21. Ki 67 immunostaining in melanocytic skin tumours: Correlation with histologic parameters
22. Mitotic indices, anti-PCNA immunostaining and AgNORs in thick cutaneous melanomas displaying paradoxical behaviour
23. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous malignant melanoma
24. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma
25. p53 protein and Ki-67 expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin
26. Prognostic value of biomarkers in malignant melanoma
27. Prognostic significance of proliferation and motility in primary malignant melanoma of the skin
28. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions: A quantitative immunohistochemical study
29. Cell proliferation markers in predicting metastases in malignant melanoma
30. The histogenesis and biologic behavior of primary human malignant melanomas of the skin
31. Prognostic index in malignant melanoma
32. Malignant melanoma of the skin
33. Prognostic index for malignant melanoma
34. Model predicting survival in stage I melanoma based on tumour progression
35. Pathologic prognostic factors for cutaneous malignant melanoma: The Western Canada Melanoma Study
36. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma
37. Mitosis counts: Reproducibility and significance in grading of malignancy
38. Does delay in fixation affect the number of mitotic figures in processed tissue?
39. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables
40. A computerized mathematical model and scoring system for predicting outcome in melanoma patients